Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma

Jihye Cha, Jinsil Seong, Ik Jae Lee, Jun Won Kim, KwangHyub Han

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: Sorafenib is an effective systemic agent for advanced hepatocellular carcinoma. To increase its efficacy, we evaluated the feasibility and benefit of sorafenib combined with radiotherapy. Materials and Methods: From July 2007 to July 2011, 31 patients were treated with a daily dose of 800 mg of sorafenib and radiotherapy. Among them, 13 patients who received radiotherapy on the bone metastasis were excluded. Thirteen patients received 30-54 Gy of radiotherapy on the primary tumor (primary group) and 5 patients received 30-58.4 Gy on the measurable metastatic lesions (measurable metastasis group). Tumor responses at 1 month after the completion of radiotherapy and overall survival were evaluated. Results: The in-field response rate was 100% in the primary group and 60% in the measurable metastasis group. A decrease of more than 80% in the tumor marker α-fetoprotein was observed in 7 patients in the primary group (54%). Toxicities of grades 3-4 were hand-foot syndrome in 3 (17%) patients, duodenal bleeding in 1 (6%) patient, thrombocytopenia in 3 (17%) patients and elevation of aspartate transaminase in 1 (6%) patient. The median overall survival was 7.8 months (95% confidence interval, 3.0-12.6). Conclusion: The combined treatment of sorafenib and radiotherapy was feasible and induced substantial tumor responses in the target lesions. The results of this study emphasize the importance of individualized approach in the management of advanced hepatocellular carcinoma and encourage the initiation of a controlled clinical trial.

Original languageEnglish
Pages (from-to)1178-1185
Number of pages8
JournalYonsei medical journal
Volume54
Issue number5
DOIs
Publication statusPublished - 2013 Sep 1

Fingerprint

Hepatocellular Carcinoma
Radiotherapy
Neoplasm Metastasis
Hand-Foot Syndrome
Fetal Proteins
sorafenib
Neoplasms
Survival
Controlled Clinical Trials
Tumor Biomarkers
Aspartate Aminotransferases
Confidence Intervals
Hemorrhage
Bone and Bones

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{387a45e3df9b46269637d0d316afaf06,
title = "Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma",
abstract = "Purpose: Sorafenib is an effective systemic agent for advanced hepatocellular carcinoma. To increase its efficacy, we evaluated the feasibility and benefit of sorafenib combined with radiotherapy. Materials and Methods: From July 2007 to July 2011, 31 patients were treated with a daily dose of 800 mg of sorafenib and radiotherapy. Among them, 13 patients who received radiotherapy on the bone metastasis were excluded. Thirteen patients received 30-54 Gy of radiotherapy on the primary tumor (primary group) and 5 patients received 30-58.4 Gy on the measurable metastatic lesions (measurable metastasis group). Tumor responses at 1 month after the completion of radiotherapy and overall survival were evaluated. Results: The in-field response rate was 100{\%} in the primary group and 60{\%} in the measurable metastasis group. A decrease of more than 80{\%} in the tumor marker α-fetoprotein was observed in 7 patients in the primary group (54{\%}). Toxicities of grades 3-4 were hand-foot syndrome in 3 (17{\%}) patients, duodenal bleeding in 1 (6{\%}) patient, thrombocytopenia in 3 (17{\%}) patients and elevation of aspartate transaminase in 1 (6{\%}) patient. The median overall survival was 7.8 months (95{\%} confidence interval, 3.0-12.6). Conclusion: The combined treatment of sorafenib and radiotherapy was feasible and induced substantial tumor responses in the target lesions. The results of this study emphasize the importance of individualized approach in the management of advanced hepatocellular carcinoma and encourage the initiation of a controlled clinical trial.",
author = "Jihye Cha and Jinsil Seong and Lee, {Ik Jae} and Kim, {Jun Won} and KwangHyub Han",
year = "2013",
month = "9",
day = "1",
doi = "10.3349/ymj.2013.54.5.1178",
language = "English",
volume = "54",
pages = "1178--1185",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "5",

}

Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma. / Cha, Jihye; Seong, Jinsil; Lee, Ik Jae; Kim, Jun Won; Han, KwangHyub.

In: Yonsei medical journal, Vol. 54, No. 5, 01.09.2013, p. 1178-1185.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma

AU - Cha, Jihye

AU - Seong, Jinsil

AU - Lee, Ik Jae

AU - Kim, Jun Won

AU - Han, KwangHyub

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Purpose: Sorafenib is an effective systemic agent for advanced hepatocellular carcinoma. To increase its efficacy, we evaluated the feasibility and benefit of sorafenib combined with radiotherapy. Materials and Methods: From July 2007 to July 2011, 31 patients were treated with a daily dose of 800 mg of sorafenib and radiotherapy. Among them, 13 patients who received radiotherapy on the bone metastasis were excluded. Thirteen patients received 30-54 Gy of radiotherapy on the primary tumor (primary group) and 5 patients received 30-58.4 Gy on the measurable metastatic lesions (measurable metastasis group). Tumor responses at 1 month after the completion of radiotherapy and overall survival were evaluated. Results: The in-field response rate was 100% in the primary group and 60% in the measurable metastasis group. A decrease of more than 80% in the tumor marker α-fetoprotein was observed in 7 patients in the primary group (54%). Toxicities of grades 3-4 were hand-foot syndrome in 3 (17%) patients, duodenal bleeding in 1 (6%) patient, thrombocytopenia in 3 (17%) patients and elevation of aspartate transaminase in 1 (6%) patient. The median overall survival was 7.8 months (95% confidence interval, 3.0-12.6). Conclusion: The combined treatment of sorafenib and radiotherapy was feasible and induced substantial tumor responses in the target lesions. The results of this study emphasize the importance of individualized approach in the management of advanced hepatocellular carcinoma and encourage the initiation of a controlled clinical trial.

AB - Purpose: Sorafenib is an effective systemic agent for advanced hepatocellular carcinoma. To increase its efficacy, we evaluated the feasibility and benefit of sorafenib combined with radiotherapy. Materials and Methods: From July 2007 to July 2011, 31 patients were treated with a daily dose of 800 mg of sorafenib and radiotherapy. Among them, 13 patients who received radiotherapy on the bone metastasis were excluded. Thirteen patients received 30-54 Gy of radiotherapy on the primary tumor (primary group) and 5 patients received 30-58.4 Gy on the measurable metastatic lesions (measurable metastasis group). Tumor responses at 1 month after the completion of radiotherapy and overall survival were evaluated. Results: The in-field response rate was 100% in the primary group and 60% in the measurable metastasis group. A decrease of more than 80% in the tumor marker α-fetoprotein was observed in 7 patients in the primary group (54%). Toxicities of grades 3-4 were hand-foot syndrome in 3 (17%) patients, duodenal bleeding in 1 (6%) patient, thrombocytopenia in 3 (17%) patients and elevation of aspartate transaminase in 1 (6%) patient. The median overall survival was 7.8 months (95% confidence interval, 3.0-12.6). Conclusion: The combined treatment of sorafenib and radiotherapy was feasible and induced substantial tumor responses in the target lesions. The results of this study emphasize the importance of individualized approach in the management of advanced hepatocellular carcinoma and encourage the initiation of a controlled clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=84881009749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881009749&partnerID=8YFLogxK

U2 - 10.3349/ymj.2013.54.5.1178

DO - 10.3349/ymj.2013.54.5.1178

M3 - Article

VL - 54

SP - 1178

EP - 1185

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 5

ER -